日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

BRAF融合基因的肿瘤非特异性基因组和临床分析可识别可操作的靶点

Chen, Monica F; Yang, Soo-Ryum; Tao, Jessica J; Desilets, Antoine; Diamond, Eli L; Wilhelm, Clare; Rosen, Ezra; Gong, Yixiao; Mullaney, Kerry; Torrisi, Jean; Young, Robert J; Somwar, Romel; Yu, Helena A; Kris, Mark G; Riely, Gregory J; Arcila, Maria E; Ladanyi, Marc; Donoghue, Mark T A; Rosen, Neal; Yaeger, Rona; Drilon, Alexander; Murciano-Goroff, Yonina R; Offin, Michael

Synoptic Reporting for Pretreatment CT Examination in Patients With Advanced Ovarian Cancer: Impact on Documentation of Disease Sites and Physician Satisfaction

晚期卵巢癌患者治疗前CT检查的概要报告:对疾病部位记录和医生满意度的影响

Andrieu, Pamela Causa; Nikolovski, Ines; Juluru, Krishna; Sadowski, Elizabeth; Gangai, Natalie; Zheng, Junting; Capanu, Marinela; Praiss, Aaron M; Nougaret, Stephanie; Shinagare, Atul B; Ma, Weining; Torrisi, Jean M; Sonoda, Yukio; Chi, Dennis S; Lakhman, Yulia

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Zenocutuzumab 是一种 HER2xHER3 双特异性抗体,可有效治疗由 NRG1 基因重排驱动的肿瘤

Schram Alison M, Odintsov Igor, Espinosa-Cotton Madelyn, Khodos Inna, Sisso Whitney J, Mattar Marissa S, Lui Allan J W, Vojnic Morana, Shameem Sara H, Chauhan Thrusha, Torrisi Jean, Ford Jim, O'Connor Marie N, Geuijen Cecile A W, Schackmann Ron C J, Lammerts van Bueren Jeroen J, Wasserman Ernesto, de Stanchina Elisa, O'Reilly Eileen M, Ladanyi Marc, Drilon Alexander, Somwar Romel

Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study

肾细胞癌患者mTOR抑制剂相关性肺炎的波动模式:一项回顾性观察研究

Gluskin, Jill; Plodkowski, Andrew; Girshman, Jeffrey; Sarasohn, Debra; Viteri-Jusué, Ainhoa; Hayan, Sumar; Torrisi, Jean

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

度伐利尤单抗联合叶酸受体α疫苗TPIV200治疗晚期卵巢癌患者的安全性、免疫原性和临床疗效:一项II期试验

Zamarin, Dmitriy; Walderich, Sven; Holland, Aliya; Zhou, Qin; Iasonos, Alexia E; Torrisi, Jean M; Merghoub, Taha; Chesebrough, Lewis F; Mcdonnell, Autumn S; Gallagher, Jacqueline M; Li, Yanyun; Hollmann, Travis J; Grisham, Rachel N; Erskine, Courtney L; Block, Mathew S; Knutson, Keith L; O'Cearbhaill, Roisin E; Aghajanian, Carol; Konner, Jason A

A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative

一项旨在改善晚期卵巢癌患者初次肿瘤细胞减灭术疗效的多模式分诊算法:纪念斯隆-凯特琳癌症中心卵巢癌团队计划

Straubhar, Alli M; Filippova, Olga T; Cowan, Renee A; Lakhman, Yulia; Sarasohn, Debra M; Nikolovski, Ines; Torrisi, Jean M; Ma, Weining; Abu-Rustum, Nadeem R; Gardner, Ginger J; Sonoda, Yukio; Zivanovic, Oliver; Chi, Dennis S; Long Roche, Kara

AKT Inhibition in Solid Tumors With AKT1 Mutations

AKT抑制剂在伴有AKT1突变的实体瘤中的应用

Hyman, David M; Smyth, Lillian M; Donoghue, Mark T A; Westin, Shannon N; Bedard, Philippe L; Dean, Emma J; Bando, Hideaki; El-Khoueiry, Anthony B; Pérez-Fidalgo, José A; Mita, Alain; Schellens, Jan H M; Chang, Matthew T; Reichel, Jonathan B; Bouvier, Nancy; Selcuklu, S Duygu; Soumerai, Tara E; Torrisi, Jean; Erinjeri, Joseph P; Ambrose, Helen; Barrett, J Carl; Dougherty, Brian; Foxley, Andrew; Lindemann, Justin P O; McEwen, Robert; Pass, Martin; Schiavon, Gaia; Berger, Michael F; Chandarlapaty, Sarat; Solit, David B; Banerji, Udai; Baselga, José; Taylor, Barry S